Dupilumab in CRSsNP
Phase 2
Completed
NCT04678856
| Condition | Chronic Rhinosinusitis Without Nasal Polyps, Sinusitis, Chronic Sinusitis, Sinus Disorder |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Sanofi |
|---|
| Status | Completed |
|---|
| Enrollment | 71 participants |
|---|
| Interventions | Dupilumab SAR231893 |
|---|
| Start date | Dec 2, 2020 |
|---|
| Completion date | Nov 14, 2023 |
|---|
| Results posted | Dec 18, 2024 |
|---|
Summary
Primary Objective: To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on computerized tomography (CT) scan in the dupilumab group only Secondary Objectives: * To evaluate the efficacy of dupilumab as assessed by the reduction at Week 24 in sinus opacification on CT scan and sinus total symptom score (sTSS) compared to placebo * To evaluate the safety and tolerability of dupilumab in CRSsNP patients compared to placebo * To evaluate the pharmacokinetics (PK) of dupilumab in CRSsNP patients compared to placebo * Assessment of immunogenicity to dupilumab over time compared to placebo
Change From Baseline to Week 24 in Opacification of Sinuses Assessed by Computed Tomography (CT) Scan Using the Lund Mackay (LMK) Score in Dupilumab Group
Baseline (Day 1) and Week 24 · Score on a scale
| Dupilumab 300 mg q2w | -6.63 ± 3.91 Score on a scale |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.